Related Experiment Video

Updated: Oct 19, 2025

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

24.5K

Transcription Factor-7-Like-2 (TCF7L2) in Atherosclerosis: A Potential Biomarker and Therapeutic Target

Junyi Li1, Li Zhou2, Xinping Ouyang3

  • 1School of Nursing, Hengyang Medical College, University of South China, Hengyang, China.

Frontiers in Cardiovascular Medicine
|September 27, 2021
PubMed

Insights

Transcription factor-7-like-2 (TCF7L2) has anti-atherosclerotic effects by regulating metabolism and inflammation. A specific TCF7L2 variant links diabetes risk to cardiovascular disease, highlighting its therapeutic potential.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Genetics

Background:

  • Transcription factor-7-like-2 (TCF7L2) is a key regulator in the T-cell factor/lymphoid enhancer factor (TCF/LEF) family.
  • TCF7L2 influences crucial physiological and pathological processes, including metabolic homeostasis and inflammation.
  • A specific TCF7L2 variant, rs7903146, is linked to type 2 diabetes and cardiovascular disease susceptibility.

Purpose of the Study:

  • To review the anti-atherosclerotic effects of TCF7L2.
  • To elucidate the molecular mechanisms underlying TCF7L2's function in atherosclerosis.
  • To explore TCF7L2's potential as a biomarker and therapeutic target for cardiovascular diseases.

Main Methods:

  • Literature review of studies on TCF7L2 and atherosclerosis.
  • Analysis of molecular pathways regulated by TCF7L2.
  • Examination of the genetic link between TCF7L2 variants, diabetes, and cardiovascular disease.

Main Results:

  • TCF7L2 demonstrates significant anti-atherosclerotic properties.
  • Mechanisms include regulating metabolic homeostasis, macrophage polarization, and neointimal hyperplasia.
  • The rs7903146 variant connects metabolic dysfunction to atherosclerosis development.

Conclusions:

  • TCF7L2 plays a multifaceted role in preventing atherosclerosis.
  • Understanding TCF7L2 mechanisms offers insights into the link between diabetes and cardiovascular disease.
  • TCF7L2 presents a promising target for novel cardiovascular disease therapies and diagnostic biomarkers.
Keywords:
CVDTCF7L2atherosclerosismetabolismrs7903146

More Related Videos

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.5K
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.4K

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
66
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
88
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
184
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.0K
Inflammation01:38

Inflammation

Overview
56.2K